Replies to post #227598 on NorthWest Biotherapeutics Inc (NWBO)

[pgsd]

"the company’s shares fizzled after their debut but have rallied in 2019. While the stock is down 18% from its highs earlier this month, it’s still trading around the $23 a share IPO price. Wall Street analysts have remained bullish despite the volatility, saying sales of the vaccine platform could reach as high as $35 billion"

[jondoeuk]

No, but many are working on neoantigen vaccines. MRNA have a collaboration with MRK https://www.fiercebiotech.com/biotech/moderna-grabs-125m-expanded-merck-cancer-vaccine-collab

MRNA also has three intratumoral candidates, mRNA-2416 (OX40L), mRNA-2752 (OX40L + IL-23 + IL-36y) and MEDI1191 (IL-12). The latter is another collaboration with AZN https://www.astrazeneca.com/media-centre/press-releases/2016/AstraZeneca-and-Moderna-Therapeutics-announce-new-collaboration-to-co-develop-and-co-commercialise-immuno-oncology-mRNA-therapeutics-11012016.html#